Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) among Vaccinated Young Women during the First 8 Years after HPV Vaccine Introduction in a Community

Clinical Infectious Diseases

Volumn 63, Issue 10, 2016, Pages 1281-1287

  Kahn, Jessica A ^a   Widdice, Lea E ^a   Ding, Lili ^a   Huang, Bin ^a   Brown, Darron R ^b   Franco, Eduardo L ^c   Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

adolescent; herd protection; papillomavirus vaccines; prevalence; women

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROPENSITY SCORE; SEXUALITY; VACCINATION; WART VIRUS; CROSS-SECTIONAL STUDY; HERD IMMUNITY; IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; YOUNG ADULT;

EID: 84994410098     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw533     Document Type: Article

References (43)

1. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
2. Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007; 356:1915-27.
3. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
4. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
5. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29.
7. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-9.
8. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:630-2.
9. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8.
10. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28:4731-7.
11. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(suppl 1):S97-106.
12. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/ 18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743-53.
13. Chow EP, Danielewski JA, Fehler G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 2015; 15:1314-23.
14. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130:e249-56.
15. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 2008; 111:1103-10.
16. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003; 14:300-6.
17. Kahn JA, Bernstein DI, Rosenthal SL, et al. Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect 2005; 81:408-14.
18. Wetzel C, Tissot A, Kollar LM, Hillard PA, Stone R, Kahn JA. Development of an HPV educational protocol for adolescents. J Pediatr Adolesc Gynecol 2007; 20:281-7.
19. Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) 2009; 18:1679-86.
20. Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL, Kahn JA. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of lowincome young women. J Clin Virol 2009; 46:107-11.
21. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36:3020-7.
22. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61.
23. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399-424.
24. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika 2000; 87:706-10.
25. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149-56.
26. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11:482-7.
27. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006; 26:38-47.
28. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States.MMWRMorb Mortal Wkly Rep 2013; 62:591-5.
29. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26(suppl 10):K1-16.
30. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124:2375-83.
31. Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129:433-9.
32. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012; 30:5496-9.
33. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51.
34. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
35. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32:26-32.
36. Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382:1795-806.
37. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110:2804-11.
38. Soderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 2014; 23:2757-64.
39. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:1-9.
40. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:784-92.
41. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-92.
42. Stupiansky NW, Zimet GD, Cummings T, Fortenberry JD, Shew M. Accuracy of self-reported human papillomavirus vaccine receipt among adolescent girls and their mothers. J Adolesc Health 2012; 50:103-5.
43. Thomas R, Higgins L, Ding L, Widdice LE, Chandler E, Kahn JA. Factors associated with HPV vaccine initiation, vaccine completion, and accuracy of self-reported vaccination status among 13-to 26-year-old men. Am J Men's Health 2016; pii:1557988316645155.